CDC Issues Statement on Results from RTS,S/AS01 Malaria Vaccine Trial

Article

Thomas R. Frieden, MD, MPH, director of the Centers for Disease Control and Prevention (CDC) and administrator of the Agency for Toxic Substances and Disease Registry, has made the following statement regarding results from the RTS,S/AS01 Malaria Vaccine Trial:

"The Centers for Disease Control and Prevention welcomes the announcement today that results from the clinical trial in Africa of a malaria vaccine candidate show it prevented about half of malaria cases, including the most severe, in young children.

The RTS,S/AS01 study results, published in the New England Journal of Medicine, are a promising advance in development of a malaria vaccine for African children, which, if successful, could save hundreds of thousands of lives. In 2009, malaria caused the deaths of nearly 800,000 people; approximately 90 percent were children in Africa.

Children ages 5-17 months were enrolled in the trial at 11 sites in seven African countries. The children who received the vaccine had approximately half the number of clinical and severe malaria cases than children in the comparison group, which received other vaccines, either rabies or meningococcal. CDC, in collaboration with the Kenya Medical Research Institute, led the trial at one site in western Kenya.

Still to come are analyses of how well the RTS,S/AS01 vaccine works in young infants (aged 6-12 weeks) when provided with their routine childhood immunizations, and how long the vaccine is protective. Those data, expected in 2012 and 2014, respectively, will be critical to understanding how the vaccine may be used to control malaria.

Its important to note that the vaccine provided this protection in settings where there is ongoing use of other effective malaria prevention and treatment interventions: bed nets, antimalarial drugs, indoor residual insecticide spraying to prevent mosquito-borne transmission, and drugs to protect pregnant women and their fetuses from malarias adverse effects. Thanks to sharp increases in global funding for malaria during the past decade, many African countries have been able to scale up the distribution and use of these safe, effective, and affordable life-saving interventions. As a result, many countries have seen decreases of up to 50 percent in deaths of children younger than 5 years (PMI Fifth Annual Report, April 2011).

The Roll Back Malaria Partnership, which includes CDC, is working to achieve near zero preventable malaria deaths. These promising vaccine trial results add to the hope that adding an effective vaccine to current malaria interventions will move us closer to that goal."

Related Videos
An eye instrument holding an intraocular lens for cataract surgery. How to clean and sterilize it appropriately?   (Adobe Stock 417326809By Mohammed)
Christopher Reid, PhD  (Photo courtesy of Christopher Reid, PhD)
Paper with words antimicrobial resistance (AMR) and glasses.   (Adobe Stock 126570978 by Vitalii Vodolazskyi)
3D illustration: Candida auris   (Adobe Stock 635576411 By Niamh )
 MIS-C (Adobe Stock 350657530 by Bernard Chantal)
Set of white bottles with cleaning liquids on the white background. (Adobe Stock 6338071172112 by zolnierek)
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
Related Content